TY - JOUR
T1 - Development of a Bispecific Antibody Targeting CD30 and CD137 on Hodgkin and Reed-Sternberg Cells
AU - Rajendran, Sakthi
AU - Li, Yating
AU - Ngoh, Evelyn
AU - Wong, Hiu Yi
AU - Cheng, Man Si
AU - Wang, Cheng I.
AU - Schwarz, Herbert
N1 - Publisher Copyright:
© Copyright © 2019 Rajendran, Li, Ngoh, Wong, Cheng, Wang and Schwarz.
PY - 2019/9/24
Y1 - 2019/9/24
N2 - Hodgkin Lymphoma (HL) is a malignancy that frequently affects young adults. Although, there are effective treatments not every patient responds, necessitating the development of novel therapeutic approaches, especially for relapsed and refractory cases. The two TNF receptor family members CD30 and CD137 are expressed on Hodgkin and Reed Sternberg (HRS) cells, the malignant cells in HL. We found that this co-expression is specific for HRS cells. Based on this discovery we developed a bispecific antibody that binds preferentially to the CD30, CD137-double positive HRS cells. The CD30, CD137 bispecific antibody gets internalized into HRS cells opening up the possibility to use it as a carrier for a toxin. This antibody also induces antibody-dependent, cell-mediated cytotoxicity in CD30, CD137-double positive HRS cells. The enhances specificity of the CD30, CD137 bispecific antibody to HRS cells makes it a promising candidate for development as a novel HL treatment.
AB - Hodgkin Lymphoma (HL) is a malignancy that frequently affects young adults. Although, there are effective treatments not every patient responds, necessitating the development of novel therapeutic approaches, especially for relapsed and refractory cases. The two TNF receptor family members CD30 and CD137 are expressed on Hodgkin and Reed Sternberg (HRS) cells, the malignant cells in HL. We found that this co-expression is specific for HRS cells. Based on this discovery we developed a bispecific antibody that binds preferentially to the CD30, CD137-double positive HRS cells. The CD30, CD137 bispecific antibody gets internalized into HRS cells opening up the possibility to use it as a carrier for a toxin. This antibody also induces antibody-dependent, cell-mediated cytotoxicity in CD30, CD137-double positive HRS cells. The enhances specificity of the CD30, CD137 bispecific antibody to HRS cells makes it a promising candidate for development as a novel HL treatment.
KW - CD137
KW - CD30
KW - Hodgkin lymphoma
KW - bispecific antibodies
KW - immunotherapy
UR - https://www.webofscience.com/wos/woscc/full-record/WOS:000487655000001
UR - https://openalex.org/W2972849862
UR - https://www.scopus.com/pages/publications/85073031959
U2 - 10.3389/fonc.2019.00945
DO - 10.3389/fonc.2019.00945
M3 - Journal Article
SN - 2234-943X
VL - 9
JO - Frontiers in Oncology
JF - Frontiers in Oncology
M1 - 945
ER -
